Edwards Lifesciences Reports First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Edwards Lifesciences (EW) PT Raised to $125 at Leerink Partners
April 27, 2016 12:44 PM EDTLeerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted is price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $115.00) following continued strong results.
Antalffy commented, "Last night, EW reported yet another quarter of better than-expected sales -- now its 8th consecutive quarter of sales outperformance -- with 1Q16 adjusted sales of $695.6M (+18% y/y, +19% ex. FX), coming in ~$27M ahead of us and over $30M ahead of the Street. Again, stronger... More
Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
April 27, 2016 8:19 AM EDTJefferies analyst Raj Denhoy reiterated a Buy rating and raised his price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $105.00) following strong results and outlook.
Denhoy commented, "EW delivered another exceptionally strong quarter. US TAVR sales were up a remarkable 64%and this was before the... More
Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
April 27, 2016 8:14 AM EDTPiper Jaffray analyst Brooks West raised his price target on Overweight-rated Edwards Lifesciences (NYSE: EW) to $123.00 (from $97.00) following another 'beat and raise' quarter.
West commented, "Edwards Lifesciences posted a strong beat-and-raise 1Q16 including revenue of $697.3M vs. consensus $664.2M (+20% y/y) and adjusted EPS of $0.71 vs. consensus... More
Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
April 26, 2016 4:21 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.71, $0.05 better than the analyst estimate of $0.66. Revenue for the quarter came in at $697.3 million versus the consensus estimate of $664.95 million.
"We are very pleased to report a strong start to 2016," said Michael A. Mussallem, chairman and CEO.... More
